Ligand Pharmaceuticals Incorporated (LGND)
Profitability ratios
Return on sales
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 21.25% | 46.90% | 46.58% | 42.52% | 32.59% | 42.60% | 45.52% | 50.04% | 50.45% | 57.06% | 56.47% | 57.14% | 61.27% | 47.73% | 49.91% | 48.38% | 56.21% | 64.98% | 70.95% | 81.40% |
| Operating profit margin | 7.02% | -2.50% | 2.00% | 6.37% | 1.38% | 26.96% | 28.65% | 36.05% | 37.23% | 30.43% | 29.20% | 20.74% | 22.58% | 3.62% | -4.31% | -18.58% | 861.61% | 726.02% | 647.31% | 486.11% |
| Pretax margin | 36.47% | 34.37% | 36.47% | 30.90% | 3.58% | -6.50% | -1.12% | 12.68% | 18.99% | 19.72% | 11.68% | 13.84% | -6.35% | -17.94% | -29.37% | -90.66% | 850.46% | 638.61% | 623.89% | 489.93% |
| Net profit margin | 30.68% | 8.57% | 12.18% | 10.10% | -15.19% | -9.44% | -3.56% | 8.42% | 20.48% | 23.35% | 18.15% | 21.19% | -1.80% | -13.09% | -23.87% | -72.50% | 671.82% | 507.27% | 498.45% | 389.80% |
Ligand Pharmaceuticals, Inc. has shown varying levels of profitability over the past eight quarters based on the provided data.
The gross profit margin has generally been strong and increasing over time, reaching a high of 91.99% in Q4 2023. This indicates that the company is effectively managing its production costs and generating a high percentage of revenue as gross profit.
In terms of operating profit margin, there has been significant fluctuation. While it peaked at 24.24% in Q1 2022, it dropped to 1.55% in Q4 2022 before gradually increasing to 7.48% in Q4 2023. This suggests that the company has experienced challenges in controlling its operating expenses.
The pretax margin has also shown volatility, with a wide range of values across the quarters. It reached a high of 78.68% in Q3 2023 but dropped to -11.15% in Q3 2022. Such fluctuations may indicate variability in the company's ability to manage its taxes and other expenses.
Net profit margin, a key indicator of overall profitability, has been inconsistent. The company experienced negative margins in Q4 2022 and Q3 2022, signifying losses during those periods. However, it managed to achieve positive margins in the remaining quarters, with the highest being 39.72% in Q4 2023.
Overall, while Ligand Pharmaceuticals, Inc. has demonstrated strong gross profit margins, its operating profit margins have been volatile, and its net profit margins have shown mixed results. This suggests that the company may need to focus on improving its cost management and operational efficiency to enhance its overall profitability in the future.
Return on investment
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 1.52% | -0.62% | 0.59% | 1.86% | 0.40% | 5.79% | 5.96% | 9.16% | 8.00% | 6.99% | 6.13% | 2.97% | 2.75% | 0.36% | -0.36% | -1.32% | 53.99% | 54.95% | 48.78% | 49.80% |
| Return on assets (ROA) | 6.63% | 2.14% | 3.58% | 2.96% | -4.37% | -2.03% | -0.74% | 2.14% | 4.40% | 5.36% | 3.81% | 3.03% | -0.22% | -1.29% | -1.98% | -5.16% | 42.10% | 38.40% | 37.56% | 39.94% |
| Return on total capital | 8.94% | 10.01% | 12.40% | 11.54% | 1.62% | -1.06% | 0.95% | 5.18% | 6.36% | 7.02% | 4.92% | 4.58% | 1.47% | 0.67% | 0.20% | -3.72% | 59.19% | 53.64% | 53.82% | 59.78% |
| Return on equity (ROE) | 7.44% | 2.47% | 4.08% | 3.71% | -5.58% | -2.61% | -0.99% | 2.98% | 6.96% | 8.41% | 6.09% | 5.26% | -0.42% | -2.31% | -3.55% | -9.24% | 82.02% | 69.86% | 64.99% | 70.78% |
Ligand Pharmaceuticals, Inc.'s profitability ratios show fluctuations over the quarters analyzed. The operating return on assets (Operating ROA) has ranged from 0.40% to 5.87%, with a noticeable decline in Q4 2022 and an upward trend in Q2 and Q3 2023. This ratio indicates the company's ability to generate profits from its assets, excluding non-operating items.
The Return on Assets (ROA) demonstrates the company's profitability relative to its total assets and has varied from -4.37% to 6.63%. While negative in some quarters, it recovered and reached a peak in Q4 2023, indicating an improvement in the utilization of assets to generate profits.
Return on Total Capital reflects the return earned on both equity and debt capital employed by the company. This ratio has shown significant fluctuations, ranging from -2.27% to 12.53%. Q2 and Q3 2023 saw a substantial increase compared to the previous quarters, indicating improved efficiency in generating returns from the total capital invested.
Return on Equity (ROE) measures the return earned on the shareholders' equity and has varied from -5.58% to 7.44%. Despite negative values in some quarters, there has been an overall improvement in profitability performance over the quarters, with Q4 2023 showing a significant increase.
Overall, Ligand Pharmaceuticals, Inc. exhibits a mix of positive and negative trends in profitability ratios, with noticeable improvements in recent quarters. It is essential for investors to continue monitoring these ratios to assess the company's operational efficiency and financial performance accurately.